REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH
- brilaroxazine — Schizophrenia Phase 3
- brilaroxazine — Bipolar Disorder
- brilaroxazine — Major Depressive Disorder
- brilaroxazine — Attention-Deficit/Hyperactivity Disorder
5-HT1A (2 companies · 5 programs)
Companies with an active program directed at 5-HT1A.
AtaiBeckley Inc. ATAI
- mebufotenin — Treatment-Resistant Depression Phase 3